Recombinant human granulocyte colony-stimulating factor (rhG-CSF) (lenograstim) was administered to healthy subjects at doses of 2, 5 and 10 g/kg/day for 5 days (twice a day subcutaneously) to examine the optimal dose and schedule of lenograstim in mobilizing peripheral blood progenitor cells (PBSC) for allogeneic transplantation. Lenograstim administration significantly increased CD34
ipheral blood progenitor cell; allogeneic transplantation; thrombocytopenia; pharmacokinetics Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been widely used to treat patients with neutropenia during intensive chemotherapy. [1] [2] [3] Recently, rhG-CSF has been applied to peripheral blood progenitor cell (PBSC) allogeneic transplantation from healthy donors, because administration of rhG-CSF in healthy donors mobilizes a sufficient number of PBSC that can be harvested. [4] [5] [6] [7] [8] [9] [10] [11] Several preliminary studies on PBSC transplantation have been reported and the appropriate dose and schedule of rhG-CSF treatment in healthy donors have been discussed. [4] [5] [6] [7] [8] [9] [10] [11] The definitive method, however, remains controversial. 6, 9, [12] [13] [14] In addition, repeated dosing of rhG-CSF in healthy subjects has been reported to cause a variety of adverse events including bone pain, low grade fever, increases in transaminases, lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) and platelet reduction. 8, 10, [14] [15] [16] Therefore the optimized dose and duration are determined by the balance between the doserelated adverse events and the required harvest of PBSC from healthy donors. The primary aim of this study was to evaluate the relationship between the dose and mobilized PBSC count and between dose-related adverse events and the time after dosing.
Pharmacokinetic data for G-CSF are required to resolve the above issues. The kinetic disposition of G-CSF in neutropenic patients receiving chemotherapy is well established, [17] [18] [19] [20] but the dose-related kinetic profile after repeated administration in healthy subjects is relatively unexplored, particularly that concerning drug clearance. G-CSF has been reported to be cleared by a non-saturable mechanism in the kidney/spleen and by a saturable mechanism in peripheral neutrophils and progenitor cells in bone marrow. [21] [22] [23] Therefore our secondary aim was to evaluate the pharmacokinetics of G-CSF in the 5 day repeated administration study.
Materials and methods

Subjects
A total of 18 healthy male Japanese volunteers 21 to 27 years of age (mean: 23.6 years) and weighing between 51.0 and 69.5 kg (mean ± s.d.: 59.7 ± 5.3) participated in the study after giving their informed consent. Each subject was judged to be healthy on the basis of a complete physical examination, a 12-lead electrocardiogram, hemogram, coagulation profile, blood chemistry profile, and urinalysis. All subjects were normotensive and had a normal heart rate. Due to the anticipation of bone pain and fever, the volunteers were offered the possibility of taking nonsteroidal anti-inflammatory drugs (NSAID) when giving their informed consent. Ultimately, none of the volunteers received NSAID or any other medication apart from rhG-CSF throughout the study. The subjects entered the Research Ward in Kannondai Clinic (Ibaraki, Japan) at least 24 h before the study began, and stayed throughout the study period. The study protocols were approved by the Institutional Ethical Committee.
G-CSF administration and blood sampling
Lenograstim (recombinant human G-CSF; Chugai Pharmaceutical, Tokyo, Japan) was administered subcutaneously for 5 consecutive days (days 1 to 5) at a dose of 2, 5 or 10 g/kg/day in six volunteers for each rhG-CSF dose level. Each daily dose was divided into two injections to reduce subjective symptoms (1, 2.5 or 5 g/kg/twice/day, every 12 h).
Peripheral blood samples were collected every morning (before drug administration on days 1 to 5) for determining white blood cell (WBC) counts, neutrophil counts, and blood biochemistry including alkaline phosphatase (ALP), lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) from day 1 (before the 1st dose) to day 10, and then on day 17 (followup). To determine the absolute number of PBSC, heparinized peripheral blood samples were collected on days 1 (before the 1st dose), 2, 3, 4, 5, 6, 8 and 10. Serum G-CSF was measured before each lenograstim injection from day 1 to day 5, and serially from 0 to 12 h (day 1) and from 96 to 168 h (day 5). Blood samples for CD34 + cell assays were taken before dosing in the mornings of days 1 (before the 1st dose), 2, 3, 4, 5, 6, 8 and 10. Blood cell components (lymphocyte, monocyte, eosinophil, basophil, platelet, myelocyte, metamyelocyte and erythrocyte) were evaluated from day 1 (before the 1st dose) to 10 and on day 17. WBC were measured using an automated cell counter (Sysmex NE-8000: TOA, Kobe, Japan). The cell components were estimated after manual leukocyte differential.
Flow cytometric analysis of CD34 + cells and their subsets
The peripheral blood samples were also analyzed by double-color flow cytometry. 24 After lysis with NH 4 Cl, the cell concentration was adjusted to 1 × 10 6 cells/ml in PBS with 10% mouse serum. The cells were stained simultaneously with phycoerythrin (PE)-conjugated anti-CD34 antibody (Immu133) for 30 min at 4°C in the dark. As isotype controls for the staining, we used PE-conjugated mouse IgG 1 . Flow cytometric analysis was performed with a FACScan (Becton Dickinson, Tokyo, Japan). The cells were selected for their small size and the expression of the CD34 antigen.
Measurement of serum G-CSF levels
Serum samples were stored in small aliquots at −20°C until analysis. Serum G-CSF levels were measured by enzymelinked immunosorbent assay (ELISA). 25 
Pharmacokinetic analysis
Serum G-CSF concentrations were fitted to a pharmacokinetic model by the nonlinear least squares method, using the computer program Window-Nonlin (Version 4.0, SCI Software, Pharsight, Lexington, KY, USA). 26 Peak serum concentrations (C max ) and time to reach C max (t max ) were obtained from real data points. The area-under-the-curve (AUC) after a single dose was calculated using log-linear trapezoidal approximation from time 0 to the time of the last measurement in the concentration -time curve and AUC 0-ϱ was calculated by summing the AUCs obtained from 0 to the last measured serum concentration divided by elimination constant (K). The subcutaneous clearance (CL/F 0-12 h ) on day 1 was estimated from the s.c. dose/AUC 0-ϱ , and the CL/F 96 to 108 h on day 5 was estimated from the s.c. dose/AUC 96 to 108 h , where F is the subcutaneous bioavailability that could not be determined. The minimum serum concentration of G-CSF (C min ) was obtained from the real data point just before the next morning dose. Dose/C min was used in this study as a parallel and acceptable parameter to the CL/F.
Safety assessment
The subjects stayed in the research unit from day 1 to day 10. Safety evaluation of the repeated doses of rhG-CSF was based on assessments of the results of physical examinations, subjective symptoms, and vital signs including blood pressure and heart rates throughout the study period. All side-effects (adverse events) were noted on the appropriate case report forms with a brief description specifying the nature, severity, date, time of occurrence, duration, and the investigator's opinion of whether the reaction was test compound-related or incidental.
Statistical methods
Data are expressed as mean ± standard error of the mean (s.e.m.) unless otherwise indicated. Multi-group comparisons were performed by analysis of variance (ANOVA). Spearman's rank correlation coefficient (R) was calculated to estimate correlations. All the statistical analyses were performed using the Stat View program. Correlations between the pre-treatment baseline counts of CD34 + cells and the post-treatment maximal mobilized counts of CD34 + cells for three doses of lenograstim were analyzed by multiple regression analysis (SAS release 6.12 procedure Reg). A regression equation was obtained that expressed the relationship between the predicted and the observed maximal mobilized count of CD34 + cells. The minimum statistically significant level was set at P Ͻ 0.05.
Results
Effect of lenograstim treatment on WBC counts, neutrophil counts and on PBSC mobilization as CD34
+ cells Significant increases in WBC and neutrophil counts were observed in all volunteers administered 5 and 10 g/kg/day compared to 2 g/kg/day. Peripheral neutrophils increased markedly by about seven to 13-fold from the baseline count, and the peak count of approximately 40 × 10 9 /l with the two upper doses was reached on day 5. The increments were similar for 5 and 10 g/kg/day ( Figure 1b and Table 1 ). PBSC counts in peripheral blood measured as CD34
+ cells increased dose-dependently to a peak count on day 5 to 6, and the increase was approximately 14-to 44-fold compared with the corresponding predose values as shown in Table 1 and Figure 1a .
There was a significant correlation between the predose + cell count and absolute neutrophil count. Changes in absolute CD34
+ cell count (a), and absolute neutrophil count (b) with time during and after the repeated-dose administration of rhG-CSF (lenograstim) at doses of 2 (), 5 (᭹) and 10 (̆) g/kg/day (twice a day for 5 days). All data indicate mean ± s.e.m. WBC = white blood cell; ALP = alkaline phosphatase; LDH = lactase dehydrogenase; ALT = alanine aminotransferase; AST = asparate aminotransferase.
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The peak value was obtained as observed data during the study period and time to reach the peak value was defined as t max (term) is defined as the period with values exceeding the normal ranges. The fold was obtained by comparing the predose value.
baseline counts of CD34 + cells and the post-dose maximal mobilized counts of CD34 + cells for all three doses of lenograstim as determined by analysis of variance. Figure 2a demonstrates the relationship between predose CD34
+ cell counts (x-axis), maximally mobilized post-dose CD34
+ cell counts (y-axis) and rhG-CSF dose (z-axis). It indicates that higher doses of rhG-CSF and greater predose CD34 + cell counts are associated with mobilization of more CD34 + cells. A multiple regression analysis of the relationship among the predose CD34 + cell count, the maximally mobilized post-dose CD34 + cell count, and the rhG-CSF dose was performed. A highly significant correlation was observed between the observed and predicted value of the maximal post-dose mobilization of CD34 + cells by multiple regression analysis. The regression equation was: predicted maximal CD34
+ cell counts = 13.279 × dose + 28.51 × the predose count − 25.16 (contribution ratio: 65.1%) (Figure 2b ).
Serum G-CSF concentration-time relationship and pharmacokinetic parameters
After the peak serum concentration (C max ) was attained 4 h following administration, serum G-CSF declined with time in a log-linear fashion, and the decline tended to be less steep with increasing rhG-CSF dosage. The concentrationtime curves varied dose-dependently as shown in Figure 3a . On day 1 after the first dose, C max and the 12 h AUC increased dose dependently (Table 2) . However, the mini- + cell counts = 13.279 × dose + 28.51 × predose cell count − 25.16) (contribution ratio: 65.1%). The symbols indicate the value in the rhG-CSF dosing of 2 (), 5 (᭹) and 10 (̆) g/kg/day (twice a day for 5h days). mum drug level (C min ) (just before the next morning dose) increased up to day 2, then decreased gradually until day 5 despite the repeated doses. The decreases were especially marked at the doses of 5 and 10 g/kg/day (Figure 3b ). Both clearance (CL/F) and dose/C min decreased with increasing dosage on day 1 ( Table 2 ). Both parameters increased significantly at the last dose (day 5) of the 5-day repeated administration, but the magnitudes were significantly higher at the dose of 5 g/kg/day compared to 2 and 10 g/kg/day (CL/F: 199.8 ± 17.7 vs 117.9 ± 9.7 and 104.2 ± 20.6 ml/h/kg; dose/C min : 8.3 ± 1.0 vs 4.5 ± 0.7 and 5.1 ± 1.5 l/kg, respectively) ( Table 2 ). Changes in the above two parameters (CL/F, dose/C min ) with time were almost consistent on days 1 and 5. We found a highly significant correlation between absolute neutrophil counts and dose/C min for each dose (Figure 4 ).
Adverse events including laboratory test abnormalities
All subjects who received 5 and 10 g/kg/day complained of mild to moderate bone pain (peak on day 5; duration of 3 to 5 days). Transient low grade fever (duration: 1-3 days) was observed in 10 of 18 subjects (two of six for 2 g, four of six for 5 g, and four of six for 10 g/kg/day). Mild headache was complained of by three of six subjects on 5 g/kg/day and four of six subjects on 10 g/kg/day, and fatigue by two of six subjects on 5 g/kg/day and four of six subjects on 10 g/kg/day during the treatment period ( Figure 5 ). These adverse effects were tolerated without any medication and no other undesirable clinical signs or symptoms were recognized during the study period. The platelet count remained unchanged during the treatment period, but gradually decreased after treatment was completed to 72 to 57% of the predose value on days 7 to 10, and recovered to the predose value on day 17 ( Figure 6 ). Dose-dependent increases in ALP and LDH were observed, with levels above the normal ranges on days 4 to 10 and peak levels on day 6 (peak day). Similarly, dose-dependent increases in transaminases (AST, ALT) were observed and the peak was on day 10 ( Table 1) .
Discussion
The primary aim of using rhG-CSF in PBSC transplantation is to obtain sufficient mobilized PBSC (over 50/l for CD34 + cells) in healthy subjects at a rhG-CSF dose as low as possible. This target count is based on the following calculation. The target PBSC count is generally agreed to be over 5 × 10 6 CD34 + cells/kg recipient body weight. 27 Assuming an average recipient body weight of 50 kg, and
Bone Marrow Transplantation using the formula reported by Höglund et al 6 the target of mobilization is over 50 cells/l. The target PBSC counts were attained in four of six subjects receiving 5 g/kg/day and in five of six subjects receiving 10 g/kg/day, which agreed with the previous study. 6 In the present study we adopted a twice-daily administration schedule to reduce the inter-subject variability of mobilization as well as to avoid the peak serum G-CSF level related side-effects. Furthermore, in clinical settings, we can discontinue the drug more easily with the twicedaily regimen. A twice-daily dose schedule has been compared with a single-daily dose schedule by some investigators, who have reported better and shorter mobilization with a twice-daily schedule. 9, 28 However, the peak mobilization day was day 5 in our study which was similar to that observed in many single-daily dose studies. Furthermore better or shorter mobilization was also not observed in several other studies using divided-dose schedule. Eventually the mobilization results appear similar with either twicedaily or single-daily administration. The issue as to which schedule is more efficient or safe for mobilization remains controversial. In our study, doses of 5 and 10 g/kg/day were able to mobilize PBSC on day 5 but there was still inter-subject variability. We therefore attempted to analyze the relationships between the predose CD34 + cell count, the maximally mobilized post-dose CD34
+ cell count, and rhG- 
Figure 5
Adverse events after the rhG-CSF administration. Pharmacological effects, and adverse events including abnormal clinical laboratory test results during and after repeated-dose administration of rhG-CSF (lenograstim). CSF dose. Then, we found a fairly significant correlation between the observed and predicted maximally mobilized post-dose CD34 + cell counts, suggesting that we may predict the mobilized PBSC counts before the drug treatment. Subjects with a low peripheral PBSC count at baseline may not respond sufficiently to repeated doses of rhG-CSF in mobilizing PBSC. The prediction of mobilized PBSC by rhG-CSF administration in healthy subjects may be useful in PBSC transplantation.
In the present repeated dose study, in contrast to general conceptions, C min decreased gradually from day 2 despite repeated twice-a-day dosing, suggesting that G-CSF clearance may increase following repeated doses. Increased clearance following repeated doses has been reported by many investigators, [18] [19] [20] 29 but the day-by-day increase in drug clearance has not been demonstrated in healthy subjects. Saturable and non-saturable processes are involved in the elimination of G-CSF. [21] [22] [23] The G-CSF receptor on neutrophils and progenitor cells in bone marrow is thought to be one of the saturable processes, while the kidney plays a major role in non-saturable elimination of G-CSF. As already reported elsewhere, [18] [19] [20] 29 we also demonstrated a significant correlation between the increase in neutrophil count and the dose/C min value, a parameter thought to correspond to drug clearance, for all three doses. Surprisingly, the slopes of correlations for the three doses were almost the same, ranging from 0.0001491 to 0.0001589. The identical slopes for the three doses suggest that increase in neutrophils by rhG-CSF administration enhances the saturable drug clearance (depends on binding to neutrophils) at the same rate for all three doses. However, because the neutrophil counts increase with rhG-CSF dose, the absolute clearance through the saturable process increases with increasing rhG-CSF dose. Conversely, the relative contribution of unsaturable drug clearance (elimination from kidney, relatively constant) to total clearance decreases with increased dosage. This would explain the decrease in the y-intercept with increasing doses. On the other hand, the findings from dose/C min correspond with the results of CL/F on days 1 and 5. On day 1, CL/F decreased with increasing dosage, however subsequent repeated doses increased CL/F significantly on day 5 compared with day 1. As shown in Table 1 , it is uncertain why CL/F was greater at the dose of 5 g/kg/day than at 10 g/kg/day. One possible explanation of this inversion is that increases in neutrophils by these two doses are of the same magnitude and saturated elimination by neutrophil and/or progenitor cells in bone marrow probably already reaches the maximum between the doses of 5 and 10 g/kg/day. Consequently, the surplus drug reduces CL/F at the dose of 10 g/kg/day. Whatever the reason(s), this change in the drug clearance should be considered when choosing the appropriate dosage for PBSC transplantation.
Concerning the adverse events during the repeated-dose study, we observed moderate platelet reduction in a dosedependent manner. The platelet counts, despite no plasmapheresis, decreased gradually day-by-day after the termination of rhG-CSF treatment and were lowered maximally on day 10 to 57% of the pre-dose value. However, the counts were still within the normal range. A number of reports have demonstrated thrombocytopenia related to rhG-CSF treatment. 10, 14, 16 However, thrombocytopenia in these reports was caused either by apheresis or chemotherapy. Delayed-onset thrombocytopenia in healthy subjects without apheresis has not been reported in detail.
The mechanism(s) of the delayed-onset thrombocytopenia is unclear. However, there are two speculative mechanisms. First, thrombocytopenia caused by rhG-CSF administration is most likely due to redirection of hematopoiesis in the direction of neutrophil production. The megakaryocyte series may be suppressed by the excessively stimulated granulocyte series. Second, several recent reports suggested that rhG-CSF administration stimulated up to a hundred-fold increase in circulating hematopoietic progenitor cells, [30] [31] [32] resulting in the development of extramedullary hematopoiesis in reticuloendothelial organs such as the spleen and liver. Thrombocytopenia, splenic enlargement, splenomegaly, and splenic rupture have been reported in patients receiving repeated-doses of rhG-CSF. 33, 34 Therefore, delayed thrombocytopenia observed in the present study may also be due to the splenic extramedullary hematopoiesis. As shown in Figure 5 and Table 1 , the time of thrombocytopenia corresponded with the time of transaminase increase, which was possibly of liver origin, an another reticuloendothelial organ. Increased serum levels of LDH and ALP were observed prior to thrombocytopenia and transaminase increase, but just following bone pain (Figure 6 ), probably due to an increased turnover of granulocytes mobilized by rhG-CSF in healthy volunteers. These changes are all consistent with the marrow pool expansion of myelogenous progenitor cells.
In summary, these preliminary results for the purpose of PBSC transplantation suggest that repeated doses of rhG-CSF induce mobilization of PBSC in a dose-dependent manner and the predose baseline value of PBSC may predict the degree of post-dose maximal mobilization. The drug treatment may cause delayed-onset moderate thrombocytopenia and transaminase increase after administration, and drug clearance changes in a complex manner. These should be kept in mind during repeated dosing.
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